Calcium Channel Blocker Growth Forecast 2025-2034: Trends, Opportunities, and Key Insights You Need to Know
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Predicted CAGR for the Calcium Channel Blocker Market Over the Forecast Period of 2025 to 2034?
The market size for calcium channel blockers has seen a robust increase in the last few years. Its expansion is projected to rise from $15.56 billion in 2024 to approximately $16.62 billion by the year 2025, with a compound annual growth rate (CAGR) of 6.8%. The growth during the historical period can be credited to a surge in cardiovascular diseases, an aging populace, developments in medical investigations, lifestyle changes, and heightened consciousness.
There is going to be a substantial expansion in the calcium channel blocker market in the years to come. It is expected to reach a value of $22.07 billion in 2029, with a compound annual growth rate (CAGR) of 7.4%. This projected growth within the forecasted period is linked to factors like the increasing worldwide prevalence of cardiovascular diseases, the rise of personalized medicine, broader access to healthcare, the enlargement of indications, regulatory approvals, and market growth. Several trends predicted for the forecasted period encompass market growth, technological progress, regulatory changes, competitive examination, changing patient preferences, and heightened awareness.
Which Factors Are Enhancing the Growth of the calcium channel blocker Market?
The surge in cardiovascular diseases’ prevalence is predicted to propel the calcium channel blocker market’s growth. Cardiovascular disease encompasses conditions impacting the heart or blood vessels. Calcium channel blockers (CCBs) are employed to diminish the likelihood of heart failure and stroke. Therefore, the rise in cardiovascular diseases’ prevalence would result in increased demand for calcium channel blockers. For example, a report by the American College of Cardiology, a non-profit medical association based in the US, forecasted in August 2022 that all four cardiovascular risk factors would see growth from 2025 till 2060 in the United States. Diabetes is expected to see the most significant percentage increase, rising 39.3% to affect 55 million individuals, followed by dyslipidemia (a spike of 27.6% to 126 million), hypertension (ascending 25.1% to 162 million), and obesity (rising 18.3% to 126 million). The researchers also noted that stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) are forecasted to see the most substantial increases in cardiovascular disease rates, with ischemic heart disease (30.7% to 29 million) and heart attacks (16.9% to 16 million) following suit. Consequently, the rising prevalence of cardiovascular diseases is fuelling the growth of the calcium channel blocker market.
Explore Comprehensive Insights Into The Global Calcium Channel Blocker Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp
Who Are the Top Companies Driving Innovation and Growth in the Calcium Channel Blocker Market?
Major companies operating in the calcium channel blocker market include:
• Pfizer Inc._x000D_
• GlaxoSmithKline plc_x000D_
• Novartis AG_x000D_
• Bausch Health Companies Inc._x000D_
• Lupin Pharmaceuticals Inc._x000D_
What Key Trends Are Currently Impacting the Calcium Channel Blocker Market’s Development?
The prevailing trend of product innovation is bolstering the calcium channel blocker market, with key firms focusing on rolling out novel products to maintain their standing in the market. For example, CMP Pharma, a pharmaceutical constructor based in the US, pioneered the launch of Norliqva, the inaugural and exclusive oral liquid solution form of amlodipine’s besylate salt – a long-lasting calcium channel blocker in June 2022. Norliqva carries a special characteristic, being an amlodipine liquid solution targeted towards treating hypertension in individuals aged 6 years and above. It eliminates the complications and inconsistencies associated with crushing or synthesizing amlodipine tablets, assuring standardized dosage and bioequivalence. Norliqva is designed for a specific group of patients who need amlodipine but struggle with swallowing difficulties or are unable to swallow at all.
Secure Your Global Calcium Channel Blocker Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report
Which Market Segments Are Driving Strategic Growth and Trends in the Calcium Channel Blocker Market?
The calcium channel blocker market covered in this report is segmented –
1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes
2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine
2) By Benzodiazepine: Diazepam
3) By Phenylalkylamine: Verapamil
4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine
Which Geographical Regions Are Pioneering Growth in the Calcium Channel Blocker Market?
North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
How Do Experts Define the Scope of the Calcium Channel Blocker Market?
Calcium channel blockers refer to a type of drug that prevents calcium from entering the muscle cells of the heart and blood vessels. Calcium channel blockers are used to treat a variety of disorders, including high blood pressure, angina, and irregular heartbeats.
Browse Through More Similar Reports By The Business Research Company:
Angiotensin Receptor Blockers (ARBs) Global Market Report 2024
Anti-Hypertensive Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Bipolar Disorder Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
